I couldn’t be more enthusiastic about our purpose at atHeart Medical: allowing more future options for patients with atrial septal defects (ASDs) by reducing device footprint.
Our first product, the reSept ASD Occluder, is the first occluder with a metal-free, bioresorbable frame.
We are focusing on preparing initial clinical sites for our U.S. IDE pivotal trial, the FDA-approved ASCENT ASD study.
We want to expand the promising data from initial clinical experience, to establish the new standard of care for the closure of ASDs – a congenital condition affecting six in 10,000 births.
I am excited to lead atHeart Medical’s incredibly experienced team, as we hit the ground running.
Thank you for following us from our very first steps in this exciting new journey.
CEO, atHeart Medical